• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.00 In stock
1 mg $613.00 In stock
5 mg $2,453.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • D183734

    7-O-Desmethyl Rapamycin

    Rapamycin impurity

    ≥85%
  • S164098

    Seco-rapamycin

    Rapamycin analog

    ≥73%
  • P3440

    PIK-293

    p110δ PI3K inhibitor.

    ≥98%
  • T1014

    7-TES-Paclitaxel

    Synthesis impurity

    ≥95%
  • A0917

    1′-S-1′-Acetoxychavicol Acetate

    TRPA1 agonist, xanthine oxidase inhibitor.

    ≥98%
  • T9968

    Tyrphostin A25

    SK K+ channel blocker, EGFR inhibitor.

    ≥98%
  • H0002

    H8 dihydrochloride

    PKA inhibitor.

    ≥98%
  • M1676

    Methotrexate Hydrate

    DHF reductase inhibitor.

    ≥98%
  • H9612

    Hydrocortisone 21-Acetate

    Steroid hormone involved in stress signaling; g...

    ≥98%
  • D760022

    DT-2216

    BCL-XL specific degrader

    ≥98%
  • C022692

    Carbinoxamine Maleate

    Histamine H1-antagonist

    ≥98%
  • K1676

    Ketoconazole

    Imidazole; 14-α demethylase inhibitor.

    ≥98%
  • G0152

    Ganciclovir

    Nucleoside (guanosine) analog; DNA chain termin...

    ≥98%
  • C9778

    Cytarabine

    Pyrimidine nucleoside (cytidine) analog; DNA ch...

    ≥98%
  • B0396

    BAY80-6946

    p110α PI3K inhibitor.

    ≥98%
  • T3584

    Tivantinib

    MET and GSK-3α/β inhibitor.

    ≥98%
  • F285081

    Fidaxomicin

    Macrocycle

    ≥98%
  • C1644

    Celecoxib

    NSAID; COX-2 inhibitor.

    ≥99%
  • R2713

    Recombinant HCV-NS4 Antigens

    Recombinant HCV antigen fragment.

    ≥95%
  • R3010

    Recombinant Tp-chimeric protein

    Recombinant chimeric protein containing Trepone...

    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only